Covid or not, venture financing breaks records
Private biotechs attracted more venture cash in 2020 than in any other year of the current cycle.
Ash 2020 cell therapy preview – the battle for recognition
With many of the usual targets on display Fate, Celyad, Allovir and others look to maintain momentum.
With a following wind JW looks to go public
The Juno/Wuxi venture will soon become one of just a few Chinese cell therapy players with a stock exchange listing.
The first real challenge to multiple myeloma CAR-T therapy
Amgen’s AMG 420 yielded early but spectacular remissions, leaving Boehringer Ingelheim with egg on its face.
